GeneDx Holdings Corp. Stock News

GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief

GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $2.82 per share a year ago.

Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.

GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the

GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript

GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.

GeneDx Holdings Corp shares jumped 21% to $4.68 in late-morning trading on Tuesday after the provider of exome and genome testing and interpretation announced that it expects to exceed revised 2023 re

After losing some value lately, a hammer chart pattern has been formed for GeneDx Holdings Corp. (WGS), indicating that the stock has found support. This, combined with an upward trend in earnings est

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2023 Results Conference Call October 30, 2023 4:30 PM ET Company Participants Sabrina Dunbar - Chief of Staff Katherine Stueland - President and CEO Kevin Feeley

STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia

GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Tricia Truehart - Head, IR Katherine Stueland - President and CEO Kevin Feeley - CFO

STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data

GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 AM ET Company Participants Tricia Truehart - Head Investor Relations Katherine Stueland - President & Chief Execut

The genetic-testing specialist is effecting a reverse stock split. Although fully expected, this still wasn't encouraging news for shareholders.